- MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
- MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
- MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
- MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
- MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
- MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
- MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
- MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
- MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
More ▼
Key statistics
On Friday, MediciNova Inc (MNOV:NMQ) closed at 1.31, 3.97% above its 52-week low of 1.26, set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.36 |
---|---|
High | 1.36 |
Low | 1.30 |
Bid | 1.30 |
Offer | 1.52 |
Previous close | 1.32 |
Average volume | 17.73k |
---|---|
Shares outstanding | 49.05m |
Free float | 47.79m |
P/E (TTM) | -- |
Market cap | 64.74m USD |
EPS (TTM) | -0.1748 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼